Meitheal Pharmaceuticals, Inc.

The Donor Egg Meeting Charleston, SC April 24-27 With its coastal charm and renowned hospitality, Charleston, South Carolina, is an ideal setting for meaningful discussions in reproductive medicine. This week, Charleston plays host to the Donor Egg Meeting, where Meitheal’s Yolanda Smith and Brett Novak are engaging with industry leaders to explore the latest advancements in third-party reproduction. The Donor Egg Meeting brings together experts in reproductive endocrinology, embryology, and patient care to discuss innovations that enhance fertility treatment success. As a trusted partner in fertility pharmaceuticals, Meitheal Fertility is committed to supporting advancements that improve patient access and outcomes. If you're attending, be sure to connect with Yolanda and Brett to discuss how Meitheal is helping shape the future of fertility care! #Fertility #FertilityCare

Known for its coastal beauty and vibrant biotech scene, San Diego is the perfect host city for this week’s Festival of Biologics conference. Meitheal Pharmaceutical's Angie Brym and Jacque Nowik will be in attendance and are looking forward to speaking with industry leaders. The Festival of Biologics unites global experts in biologic drug development, manufacturing, and delivery to explore innovations that are shaping the future of healthcare. Meitheal is dedicated to providing high-quality, accessible pharmaceutical solutions, and we are excited to engage with industry leaders on what is next. Think sustainability. Think Meitheal.

This week, we’re taking a moment to recognize and support the many individuals and couples who are facing infertility. Infertility affects 1 in 6 people—and yet it’s something that often goes unspoken. We believe it’s important to open up the conversation, show support, and let people know: you are not alone. At Meitheal Fertility, our goal is to support this journey by providing innovative, reliable fertility treatments that make a difference. #ALLinFertility #NIAW2025 #WomensHealth #Infertility

We are excited to announce the launch of Fluorouracil Injection, USP 5 g per 100 mL (NDC 71288-154-76) in a 1 PBP vial. This addition completes our Fluorouracil product family, in conjunction with the 2.5 g per 50 mL (NDC 71288-170-75) PBP vial, which has been available since November 2024. Fluorouracil Injection is a nucleoside metabolic inhibitor indicated for the treatment of colorectal, breast, gastric, and pancreatic adenocarcinomas. At Meitheal, we remain committed to expanding access to high-quality oncology treatments. Learn more about Fluorouracil Injection, USP here: https://lnkd.in/gqyWzz9w. Think sustainability. Think Meitheal.

Meitheal Pharmaceuticals is pleased to announce the official launch of two new strengths of Cyanocobalamin Injection, USP, a treatment option for vitamin B12 deficiencies. Cyanocobalamin is an essential treatment for vitamin B12 deficiencies caused by malabsorption which may be linked to pernicious anemia, gastrointestinal conditions, post-surgical complications, and more. The launch of Cyanocobalamin Injection, USP reinforces Meitheal’s commitment to providing affordable healthcare solutions for the common good. Learn more about Cyanocobalamin Injection, USP here: https://lnkd.in/gFYHSNw5 Think sustainability. Think Meitheal.